IMM
IMMUTEP LTD ORDINARYImmutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.
IMM
IMM
IMMUTEP LTD ORDINARY
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers.
Fundamentals
Historical Data63 days
| Date | Short % | Gross Short |
|---|---|---|
| 16 July | — | — |
| 15 July | — | — |
| 14 July | — | — |
| 13 July | 2.40% | — |
| 10 July | 2.39% | — |
| 9 July | 2.39% | — |
| 8 July | 2.41% | — |
| 7 July | 2.45% | — |
| 6 July | 2.47% | — |
| 3 July | 2.48% | — |
| 2 July | 2.50% | — |
| 1 July | 2.51% | — |
Immutep LTD (IMM) Short Interest Summary
Immutep LTD (IMM) currently has 2.40% of its shares sold short (35.4 million shares, worth approximately $1.9 million), based on ASIC short position data reported on 13 July 2026 (T+4 reporting lag). That makes IMM the #139 most shorted stock on the ASX most shorted list. Short interest in IMM is down 0.07% over the past week and down 0.33% over the past month. IMM is part of the Health Care sector on the ASX.
Recent IMM Short Position History
| Date | Short % | Short Shares | Close Price |
|---|---|---|---|
| 13 July 2026 | 2.40% | 35.4M | $0.06 |
| 10 July 2026 | 2.39% | 35.2M | $0.05 |
| 9 July 2026 | 2.39% | 35.2M | $0.05 |
| 8 July 2026 | 2.41% | 35.6M | $0.05 |
| 7 July 2026 | 2.45% | 36.1M | $0.05 |
| 6 July 2026 | 2.47% | 36.4M | $0.05 |
| 3 July 2026 | 2.48% | 36.6M | $0.05 |
| 2 July 2026 | 2.50% | 36.8M | $0.06 |
| 1 July 2026 | 2.51% | 37.0M | $0.06 |
| 30 June 2026 | 2.51% | 37.0M | $0.05 |
IMM Short Selling — Frequently Asked Questions
What is Immutep LTD (IMM)'s current short interest?
Immutep LTD (IMM) currently has a short interest of 2.40% of total shares outstanding. This means 2.40% of IMM's shares have been sold short by investors who expect the price to decline. This data is sourced from ASIC reports and updated daily.
Is IMM heavily shorted on the ASX?
IMM has a relatively low short interest of 2.40%. Short interest below 5% generally suggests limited bearish sentiment from short sellers.
What does short interest mean for IMM investors?
Short interest in IMM shows the percentage of shares investors have borrowed and sold, betting the price will fall. At 2.40%, IMM's short interest is at a low level. See our short squeeze candidates and days to cover analysis for more context.
Where does this IMM short data come from?
Short position data is published by ASIC with a four trading day delay (T+4) and covers reported short positions as a percentage of total shares on issue. ASX Short Data also tracks daily gross short sales (T+1), securities lending, and director trades for IMM.